


CARDIOMETABOLIC DISEASES



Our innovation in CardioMetabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes and anticoagulation care. We are also committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts.

Our specific partnering interests offer various opportunities for collaboration on therapies that go beyond diabetes as we pursue the next wave of innovative medicines for CardioMetabolic diseases. While most of our partnering takes place between Discovery and Phase 1, we also consider exceptional opportunities in more advanced clinical stages.

Liver diseases: Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, portal hypertension

Novel obesity treatments: Novel treatments achieving weight loss > 10%

CV specialty care and type 2 diabetes: Breakthrough treatment options

For more information please contact :

Dr. Namiko Yamashita < namiko.yamashita@boehringer-ingelheim.com >

Dr. Takeshi Kono < takeshi.kono@boehringer-ingelheim.com >